Allantoin: Urea Derivative for Wound Healing and Skin Care
Allantoin is a naturally occurring diureide of glyoxylic acid and a metabolic end product of purine metabolism in many organisms. In humans, uric acid is the final product of purine catabolism, but in most other mammals, the enzyme uricase further converts uric acid to allantoin, which is then excreted in urine. Allantoin is found naturally in many plants, most notably in comfrey root (Symphytum officinale), which has traditionally been used topically for wound healing and musculoskeletal conditions. Allantoin is also present in sugar beet, wheat sprouts, and various other botanical sources.
In pharmaceutical and cosmetic applications, allantoin is valued for its multiple beneficial properties on skin and mucous membranes: it promotes cell proliferation and wound healing, acts as a mild keratolytic by softening the stratum corneum, provides moisturizing and soothing effects, and has demonstrated anti-irritant properties that make it a protective agent in formulations applied to sensitive or damaged skin. Its outstanding tolerability, absence of systemic absorption from topical application, and safety profile across all age groups including infants make it one of the most versatile and widely used ingredients in dermatological and cosmetic products.
Mechanism of Action
The pharmacological and cosmetic activity of allantoin on skin and mucous membranes involves several interrelated mechanisms. First, allantoin has keratolytic properties: it promotes the dissociation of the corneocyte protein bridges that maintain cohesion in the stratum corneum. By loosening these intercellular connections, allantoin facilitates the shedding of dead skin cells (desquamation) and softens thickened or rough skin. This keratolytic effect improves the texture of dry, calloused, or hyperkeratotic skin and facilitates the penetration of other active ingredients when allantoin is used in combination products. Second, allantoin is described as a cell-proliferating agent: it stimulates the proliferation of fibroblasts and keratinocytes, the primary cell types responsible for wound healing and epidermal regeneration. This property supports the repair of skin barrier damage, wound healing in superficial abrasions and minor wounds, and recovery of the skin after procedures or irritant exposure. Third, allantoin has demulcent and soothing properties that reduce the sensation of irritation and discomfort on inflamed or sensitive skin surfaces. It forms a protective film on mucous membranes and skin, reducing irritant contact with nerve endings. Fourth, allantoin has an established moisturizing effect through its ability to bind water and improve the water-holding capacity of the stratum corneum, contributing to skin hydration and barrier function. No clinically significant systemic absorption of allantoin from topical application has been documented under normal conditions of use, confirming its strictly local mechanism of action when applied to intact or lightly damaged skin.
Indications
Allantoin is used in both pharmaceutical preparations and cosmetic formulations. In dermatological products, it is included for the treatment and supportive care of a wide range of conditions. Minor wounds, superficial abrasions, cuts, and skin excoriations benefit from allantoin-containing preparations through promotion of healing and reduction of irritation. Dry and rough skin conditions, including xerosis, ichthyosis, and other hyperkeratotic skin conditions, respond to its keratolytic and moisturizing properties. Eczema and atopic dermatitis formulations frequently contain allantoin as a soothing and skin-barrier supporting agent alongside anti-inflammatory components. In baby care products, allantoin is used in nappy (diaper) rash creams and other infant skin preparations because of its outstanding tolerability and protective properties on the sensitive and compromised skin of neonates and infants. Allantoin is incorporated into oral care products including toothpastes and mouthwashes for its protective effect on the oral mucosa. In cosmetics, it is widely used in facial moisturizers, body lotions, after-sun products, and shaving preparations. It is a registered pharmaceutical ingredient in several countries for wound care and dermatological indications, while simultaneously being included on cosmetic approved ingredient lists with a long history of safe use. Formulations containing allantoin as the primary active ingredient are often available over the counter without prescription.
Dosage and Administration
Allantoin is incorporated into topical preparations at concentrations typically ranging from 0.1 to 2 percent, with most cosmetic formulations containing 0.1 to 0.5 percent and pharmaceutical wound-care products often containing higher concentrations up to 2 percent. It is applied directly to the affected skin area in the form of creams, ointments, gels, or lotions, typically two to four times daily or as instructed by the specific product. For wound care applications, the affected area should be cleaned before application. For dry skin conditions, application after bathing while the skin is still slightly moist can enhance the moisturizing benefit by sealing in water. For use in the oral cavity, allantoin-containing mouthwashes are used by rinsing and expectorating, and toothpastes are used as normal dental hygiene preparations. There are no established maximum dose limits for topical use due to the absence of systemic absorption, but application to large areas of severely damaged skin over prolonged periods is not standard practice and should follow specific product instructions. No dose adjustment based on age is required beyond following age-specific product recommendations; allantoin is safe for use in infants, children, adults, and the elderly when appropriate formulations are selected.
Side Effects
Allantoin has an exceptional tolerability profile and is considered one of the best-tolerated ingredients in pharmaceutical and cosmetic dermatology. Contact hypersensitivity or allergic contact dermatitis to allantoin is extremely rare and is generally considered an unusual occurrence given its long history of widespread use in skin care products globally. When hypersensitivity does occur, it manifests as the typical features of contact dermatitis: redness, itching, vesiculation, and oozing at the site of application, with potential spread to surrounding skin. Patch testing can confirm allantoin-specific sensitization if suspected. No systemic adverse effects have been reported from topical allantoin use at normal concentrations, as systemic absorption is negligible. Allantoin does not have irritant potential at standard formulation concentrations; indeed, its anti-irritant and soothing properties are among its primary pharmacological characteristics. Neonates and infants tolerate allantoin-containing diaper creams and skin preparations very well, with no documented specific concerns for this age group beyond what applies to any topical preparation (avoidance of eye contact, ensuring the product is intended for the age group, etc.).
Interactions
Given that allantoin acts exclusively at the surface of the skin and mucous membranes with no clinically relevant systemic absorption, pharmacokinetic drug interactions with systemically administered medications are not a concern. Local interactions relevant to formulation and application practice include the possibility that allantoin's keratolytic properties may modestly enhance the penetration of other active substances in combination preparations, which is generally a desired synergistic effect in pharmaceutical formulation rather than an adverse interaction. When allantoin is combined with more potent active ingredients such as topical corticosteroids or retinoids, the keratolytic effect of allantoin may theoretically enhance the penetration of these agents, though at typical allantoin concentrations this effect is mild. No clinically significant interactions between allantoin-containing preparations and other topical or systemic medications have been documented in the published literature. Allantoin is chemically stable in a wide pH range and is compatible with most common pharmaceutical and cosmetic excipients, which contributes to its versatility in formulation.
Special Notes
Allantoin's combination of wound-healing promotion, keratolytic activity, moisturizing properties, and anti-irritant effects makes it a uniquely multifunctional ingredient that straddles the boundary between pharmaceutical and cosmetic products. Its safety record across diverse populations, from premature neonates to elderly patients, and its essentially non-existent systemic toxicity profile, make it one of the most broadly applicable topical agents in medicine and personal care. In the context of wound care, it is important to note that allantoin is most appropriate for superficial wounds and minor skin injuries; deeper wounds, infected wounds, or wounds showing signs of systemic infection require appropriate medical assessment and may need systemic antibiotic therapy in addition to or instead of topical wound care products. The botanical origin of allantoin in comfrey has historical significance, but modern pharmaceutical-grade allantoin is produced synthetically and is not associated with the pyrrolizidine alkaloid concerns relevant to comfrey root preparations, which should not be applied to broken skin or taken internally. Synthetic allantoin is the standard used in all modern pharmaceutical and cosmetic formulations.
Related Topics
Frequently Asked Questions
What is the difference between allantoin and urea in skin care?
Both allantoin and urea are used as keratolytic and moisturizing agents in dermatological preparations, but they differ in mechanism, concentration requirements, and primary applications. Urea (carbamide) is a potent keratolytic at higher concentrations (10 to 40 percent), directly disrupting hydrogen bonds in the keratin protein structure of the stratum corneum and is used for thick hyperkeratotic conditions such as psoriatic plaques, calluses, and severe ichthyosis. At lower concentrations (2 to 10 percent), urea acts as a humectant. Allantoin, by contrast, is effective at much lower concentrations (0.1 to 2 percent) and is valued primarily for its wound-healing promotion, cell-proliferating activity, and soothing anti-irritant properties alongside moderate keratolytic action. Allantoin is generally milder and better suited for sensitive skin, whereas urea at therapeutic concentrations is more potent but can cause stinging on damaged or very sensitive skin.
Is allantoin safe for use on babies?
Allantoin has an extensive track record of safety in infant and neonatal skin care. It is a standard ingredient in many commercial baby barrier creams used for diaper rash prevention and treatment, and in baby lotions, washes, and moisturizers. Its anti-irritant and cell-proliferating properties are particularly beneficial in the context of diaper dermatitis, where skin integrity is compromised by exposure to urine, feces, and friction. No specific adverse effects attributable to allantoin have been reported in neonates or infants in the published literature. When choosing products for infants, caregivers should select preparations specifically formulated for infant skin, which are optimized for the unique characteristics of neonatal skin including higher permeability and a developing skin barrier, and should avoid products containing other ingredients that may be unsuitable for infants (such as certain preservatives or fragrances).
Can allantoin help with scar treatment?
Allantoin is included in several scar management products and has been studied for its potential role in scar prevention and maturation. Its cell-proliferating and keratolytic properties may help normalize the abnormal keratinocyte differentiation and excess collagen deposition that contribute to hypertrophic scars and keloids. In combination with other active ingredients such as silicone, onion extract (quercetin), or heparin, allantoin-containing preparations are used for scar softening and flattening. The evidence base for scar management with any topical preparation is generally moderate, and results vary considerably between individuals and scar types. For established keloids or severe hypertrophic scars, allantoin-containing creams are typically adjunctive to other interventions such as silicone sheets, corticosteroid injections, or laser therapy rather than primary treatments. They are most rationally used in early wound healing phases to support optimal skin repair and potentially reduce the risk of excessive scarring in wounds prone to it.
Sources
- Araújo LU et al. Allantoin: biological activity and use in cosmetics and pharmaceuticals. Rev Bras Farmacogn. 2010.
- Cosmetic Ingredient Review Expert Panel: Safety Assessment of Allantoin and Its Related Compounds as Used in Cosmetics. 2010.
- Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther. 2004.